ALK and non-small cell lung carcinoma: Our study aimed to provide detailed information on the effectiveness and safety of crizotinib treatment as well as progression patterns, sequential therapy, PFS2 and OS after crizotinib resistance in patients with advanced ALK-positive NSCLC in Chinese real-world clinical routine practice.